Kim Kardashian West Misbrands Morning Sickness Drug #noway!
Kim Kardashian West recently posted to her Instagram account a picture of herself holding a bottle of Diclegis®, a drug for morning sickness. Kim has been suffering from “pretty bad” morning sickness during the pregnancy of her second child, and her doctor recommended Diclegis, which helped her so much that she decided to partner with the company to help raise awareness about morning sickness treatment.
The FDA was not fully accepting of the social media post Kim made regarding the promotion of Diclegis, since she failed to include any risk information associated with the drug’s use and the material facts. The social media post of Kim Kardashian West holding the Diclegis bottle is concerning since it could have potentially reached tens of millions of her followers, and it suggests that the drug is safer than has been demonstrated. The post could potentially lead to false advertising charges for Duchesnay, Inc. (maker of Diclegis).
The FDA has taken action against the post, which has since been removed from Kim Kardashian West’s Instagram account. The Office of Prescription Drug Promotion (OPDP) of the FDA has requested that Duchesnay immediately cease misbranding of Diclegis and/or introducing the misbranded drug into the interstate commerce (FDA Warning Letter to Eric Gervais)
Read Kim’s full post here:
“OMG. Have you heard about this? As you guys know my #morningsickness has been pretty bad. I tried changing things about my lifestyle, like my diet, but nothing helped, so I talked to my doctor. He prescribed me #Diclegis, and I felt a lot better and most importantly, it’s been studied and there was no increased risk to the baby. I’m so excited and happy with my results that I’m partnering with Duchesnay USA to raise awareness about treating morning sickness. If you have morning sickness, be safe and sure to ask your doctor about the pill with the pregnant woman on it.???
Read the full New York Times article here.
Read the FDA Warning Letter to Duchesnay, Inc. here.
